Individuals are given one vaccination at the 14-16 years National Immunisation Program Schedule point:

  • Nimenrix protects against Meningococcal disease (types A, C, W and Y)

AusVaxSafety has been conducting surveillance of the vaccine given at the 14-16 years Schedule point on a continuous basis since 2019. The analysis has remained constant over this time and not identified any safety concerns.

The latest medical attendance rate for the 14-16 years Schedule point is below and will be updated on a quarterly basis.

 


More detailed safety data from the 14-16 years Schedule point is available from the 2020 Vaccine Safety in Australia AusVaxSafety Summary Report below.

Click here to download AusVaxSafety data from the 14-16 years schedule point for 2020

Last updated December 2021